You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Ovarian cancer

Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

  • Technology appraisal guidance
  • Reference number: TA284
  • Published:  22 May 2013
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Physicians (NCRI Gynaecological Cancer Clinical Studies Group/RCP/RCR/ACP/JCCO)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Physicians (NCRI Gynaecological Cancer Clinical Studies Group/RCP/RCR/ACP/JCCO) Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Physicians (NCRI Gynaecological Cancer Clinical Studies Group/RCP/RCR/ACP/JCCO)
25 March 2013
(323.89 Kb 34 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 22 March 2013

Back to top